Use of Anti-Dyslipidemia in Type 2 Diabetes Mellitus

Dyslipidemia is one of the most common conditions in type 2 diabetes mellitus patients. Use of anti-dyslipidemia needs to be studied because it can cause improper therapy and drug-related problems that affect patient management.

To study the use of anti-dyslipidemia in type 2 diabetes mellitus

The study was descriptive retrospective study with medical record of type 2 DM patients with dyslipidemia. Inclusion criteria were patient who was diagnosed with type 2 DM with dyslipidemia; received anti-dyslipidemia therapy; ≥20-year old male or female; and had a complete medical record. Sampling used time-limited sampling method. Data were analyzed descriptively.

Patients who met inclusion criteria were 390 people. The most commonly found laboratory data

was LDL value (96.41%). The mostly used anti-dyslipidemia therapy was HMG-CoA reductase inhibitors and fibrate. This study found potential DRP (drug interaction, drug reaction, and therapy suitablity) and actual DRP (drug side effects). In therapeutic response, there were still many patients who did not reach the expected lipid level. This showed that controlling lipid levels in patients with type 2 DM is difficult. Management of anti-dyslipidemia was not only pharmacological therapy but could also be balanced with non-pharmacological therapy to prevent other risk factors development.

Use of anti-dyslipidemia therapy in type 2 DM patients in outpatient care unit was in accordance with existing guidelines, but the therapeutic response was not in accordance with the goals of therapy.